Last reviewed 2026-04-23 · How we verify

HyperHAES vs. RA-solution/NaCl

HyperHAES is a hypertonic hydroxyethyl starch solution that restores intravascular volume and improves microcirculation through osmotic effects, compared to standard isotonic saline or Ringer's acetate.

HyperHAES is a hypertonic hydroxyethyl starch solution that restores intravascular volume and improves microcirculation through osmotic effects, compared to standard isotonic saline or Ringer's acetate. Used for Hemorrhagic shock resuscitation, Severe hypovolemia requiring rapid fluid restoration.

At a glance

Mechanism of action

HyperHAES combines a hypertonic sodium chloride solution (7.2%) with hydroxyethyl starch (HES), creating a colloid with enhanced osmotic pressure that draws fluid into the intravascular space more efficiently than crystalloid solutions. This is intended to achieve faster hemodynamic stabilization and improved tissue perfusion with smaller infusion volumes, particularly in hemorrhagic shock or severe hypovolemia. The comparison trial evaluates whether this approach reduces fluid requirements and improves outcomes versus standard crystalloid resuscitation.

Approved indications

• Hemorrhagic shock resuscitation
• Severe hypovolemia requiring rapid fluid restoration

Common side effects

• Hyperchloremic acidosis
• Acute kidney injury
• Coagulopathy
• Hypernatremia

Key clinical trials

• Fluid Shifts in Patients Treated With Therapeutic Hypothermia After Cardiac Arrest (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• HyperHAES vs. RA-solution/NaCl CI brief — competitive landscape report
• HyperHAES vs. RA-solution/NaCl updates RSS · CI watch RSS
• Haukeland University Hospital portfolio CI